PARP1 and intrahepatic cholangiocarcinoma: Considering that Dasatinib and PARP1 inhibitors have been reported in IDH1/2 mutant ICC or other cancers 54-56, we tested the effect of JQ1 and Vorinostat on clone formation ability in four ICC cell lines.